{
  "id": 531,
  "text": "[](images/2eb899782e1d08d5403b8224438819765ec844296e82ddf8c5bc3f4dc293620a.jpg) # IIB期、III期、 IVA期 ![](images/4e6bbe1724f61b2080c64175054cd6f277182ad5091f0b5767c4ac36bc1724ba.jpg) 指南推荐对于FIGO 2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: [](images/2eb899782e1d08d5403b8224438819765ec844296e82ddf8c5bc3f4dc293620a.jpg) # IIB期、III期、 IVA期 ![](images/4e6bbe1724f61b2080c64175054cd6f277182ad5091f0b5767c4ac36bc1724ba.jpg) 指南推荐对于FIGO 2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "对于FIGO 2014分期为III-IVA期的宫颈癌患者，指南推荐在进行放化疗时可以考虑加用帕博利珠单抗。这种选择可以帮助提高治疗效果，特别是在晚期阶段。帕博利珠单抗是一种免疫治疗药物，通过增强机体免疫系统来对抗癌细胞。结合放化疗使用可能有助于改善患者的预后和生存率。在治疗过程中，需根据具体病情和患者的健康状况评估是否适合使用此药物。此外，还应咨询专业医生以获取个性化的治疗建议。",
  "query": "**对于FIGO 2014分期为III-IVA期的患者，治疗中是否有推荐加入帕博利珠单抗？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: **对于FIGO 2014分期为III-IVA期的患者，治疗中是否有推荐加入帕博利珠单抗？**\n\n<reference text>: [](images/2eb899782e1d08d5403b8224438819765ec844296e82ddf8c5bc3f4dc293620a.jpg) # IIB期、III期、 IVA期 ![](images/4e6bbe1724f61b2080c64175054cd6f277182ad5091f0b5767c4ac36bc1724ba.jpg) 指南推荐对于FIGO 2014分期III-IVA期宫颈癌患者，可在放化疗中加用帕博利珠单抗。\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "对于FIGO 2014分期为III-IVA期的宫颈癌患者，指南推荐在进行放化疗时可以考虑加用帕博利珠单抗。这种选择可以帮助提高治疗效果，特别是在晚期阶段。帕博利珠单抗是一种免疫治疗药物，通过增强机体免疫系统来对抗癌细胞。结合放化疗使用可能有助于改善患者的预后和生存率。在治疗过程中，需根据具体病情和患者的健康状况评估是否适合使用此药物。此外，还应咨询专业医生以获取个性化的治疗建议。"
}